Results 181 to 190 of about 5,019,018 (303)

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

open access: yesMolecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad   +2 more
wiley   +1 more source

Editorial: Proceedings of the Inaugural ISESSAH Conference

open access: yesFrontiers in Veterinary Science, 2019
Bouda Vosough Ahmadi   +4 more
doaj   +1 more source

Assessment of animal diseases caused by bacteria resistant to antimicrobials: Swine. [PDF]

open access: yesEFSA J, 2021
EFSA Panel on Animal Health and Welfare (AHAW)   +26 more
europepmc   +1 more source

Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy

open access: yesMolecular Oncology, EarlyView.
We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen   +19 more
wiley   +1 more source

Editorial: Predicting, managing, and minimizing mycotoxicosis in farm animals

open access: yesFrontiers in Fungal Biology
Jesús Adonai Maguey-González   +3 more
doaj   +1 more source

Network Analysis of Small Ruminant Movements in Uganda: Implications for Control of Transboundary Animal Diseases. [PDF]

open access: yesTransbound Emerg Dis
Nkamwesiga J   +6 more
europepmc   +1 more source

Assessment of animal diseases caused by bacteria resistant to antimicrobials: cattle. [PDF]

open access: yesEFSA J, 2021
EFSA Panel on Animal Health and Welfare (AHAW)   +25 more
europepmc   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

open access: yesMolecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy